Limits and uncertainty all around telehealth reimbursement have always been an impediment to adoption. Through the COVID-19 emergency, that load was eased considerably, but now the new normal is beginning to consider shape. What barriers nevertheless keep on being to telehealth reimbursement, and how could possibly they be defeat? To remedy that problem, host Jonah Comstock and Health care Finance News Running Editor Susan Morse welcome McKinsey & Organization associates Oleg Bestsennyy and Gunjan Khanna.
This episode is introduced to you by BlueJeans.
Like what you hear? Subscribe to the podcast on Apple Podcasts, Spotify or Google Participate in!
- COVID-19 reimbursement improvements and which of them will adhere all around
- Adoption classes discovered and how they’ll influence reimbursement coverage
- Holistic tele-care and care over and above the video clip pay a visit to
- Impact of new entrants and innovation on the area
- Is rate-for-assistance reimbursement an innovation blocker?
- Reimbursement for distinct telehealth modalities
- Time to direct rather than comply with for private payers?
- The nevertheless-unresolved problem of induced utilization
- The rise of benefit-based mostly care and hybrid care models
- Telehealth reimbursement and wellness equity
- How are clients emotion about telehealth now?
- Final ideas: the long run of telehealth reimbursement
Extra about this episode:
Report displays ‘vast improvement’ in condition telehealth reimbursement insurance policies
COVID-19 may well forever change the telehealth landscape, from reimbursement to utilization
Telehealth reimbursement parity spurs insurance provider issues of overutilization
CMS will reimburse for eleven new telehealth companies for the duration of the public wellness emergency
Congressional motion is needed for telehealth not to return to a rural advantage, Seema Verma claims
Telehealth: A quarter-trillion-greenback write-up-COVID-19 reality? (McKinsey)
COVID-19 Shopper Health care Insights: What 2021 may well hold (McKinsey)
How COVID-19 has altered the way US buyers feel about healthcare (McKinsey)